Focusing on platelet-mediated erythromelalgia as a specific, presenting, and single sign of essential thrombocythemia (ET) we were able to define the characteristic peripheral blood and bone marrow findings in ET patients. From 1974 to 1986 we treated 20 symptomatic ET patients with microvascular circulation disturbances including erythromelalgia (N = 18), atypical or typical transient ischemic attacks (N = 6), or acute coronary ischemic syndrome (N = 3) with aspirin and one course of busulfan. The mean platelet counts before and after busulfan treatment were 1,009 (range 545-1,525) and 241 (range 159-315) x 10 9 /L, respectively. After induction of a complete remission, treatment with busulfan and aspirin was discontinued until symptoms returned. All 20 patients remained asymptomatic as long as ET was in maintained remission (platelet <350 x 10 9 /L) for 4 to 61 (mean 36) months. Eight patients became symptomatic and 4 patients remained asymp-tomatic at relapse of ET after a follow-up period of 19 to 61 and 31 to 46 months, respectively. Platelet counts at time of symptomatic relapse in the 8 patients were 410, 450, 490, 500, 515, 545, 548, and 635 x 10 9 /L and at time of asymptomatic relapse in 4 ET patients 577, 600, 648, and 725 x 10 9 /L. Based on these observations, since 1986 we followed the strategy to treat ET patients with aspirin as long as the platelet count was between 400 and 1,000 up to 1,250 x 10 9 /L. Clear indications to reduce the platelet count were bleeding, aspirin side effects, and platelets counts above 1500 x 10 9 /L. This nonleukemogenic or least toxic approach in ET is the rationale behind the normal life expectancy and subsequent thrombosis-free survival in 68 ET patients after a mean follow-up period of 6.2 years.
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The diagnostic criteria for ET proposed by the Polycythemia Vera Study Group (PVSG) in 1975 (1) were a platelet count in excess of 1000 x 109/L and a bone marrow, that shows marked megakaryocytic hyperplasia, abundant platelet clumps, absence of polycythemia vera (2), Philadelphia chromosome (Ph'), and preleukemia or myelodysplastic syndrome (MDS). The criterion of platelet count above 1,000 x 109/L resulted in the exclusion of a significant number of patients with essential thrombocythemia with a lesser degree of thrombocytosis. This prompted the PVSG in 1986 to reconsider the diagnosis of essential thrombocythemia whenever the platelet counts were above 600 x 109/L (3, 4) .
Focusing on platelet-mediated erythromelalgia as a specific, pathognomonic, presenting, and single manifestation of essential thrombocythemia (ET) we were able to document the very early stages of ET in bone marrow smears and biopsy material (5, 8) . Since 1975 we have determined the diagnostic criteria of essential thrombocythemia by careful prospective evaluation of the periph-eral blood and bone marrow specimens. Platelet count in excess of 400 x 109[L and an increase of clustered mature and enlarged megakaryocytes with hyperploid nuclei in the bone marrow biopsy material in the absence of any sign or cause of reactive thrombocytosis and no preceding or allied other subtype of myeloproloferative disorders or myelodysplastic syndrome were mandatory for the diagnosis of essential thrombocythemia (9) (10) (11) (12) . In this study we have evaluated the natural history and life expectancy in 68 aspirin-treated patients with essential thrombocythemia.
METHODS

Diagnostic criteria of essential thrombocythemia
Essential thrombocythemia and polycythemia vera were diagnosed according to the criteria proposed by the Thrombocythemia Vera Study Group (TVSG, Table 1 ) (13) . Prefibrotic early and manifest stages of idiopathic myelofibrosis (IMF) and its differentiation from ET were diagnosed according to the Cologne criteria for IMF (14, 15) .
Analysis of risk factors for thrombosis
Risk factors for thrombosis at diagnosis of ET were analyzed by stepwise logistic regression analysis. Each risk factor was also tested separately using a Chi-square test or Fisher's excel test.
Survival analysis
An overall survival curve of 68 ET patients was established according to the Kaplan-Meier method using an EGRFT software package.
TREATMENT STRATEGY
Since 1975 symptomatic ET patients with microvascular thrombotic circulation disturbances including erythromelalgia, atypical and typical transient ischemic attacks, and acute coronary syndromes were treated with aspirin and with one course of busulfan (5, 7, 16) . After induction of complete remission (i.e., platelet count below 350 x 109/L), treatment with busulfan and aspirin was discontinued until patients became symptomatic. Asymptomatic ET patients were not treated but were followed by watchful waiting until they became symptomatic and had to be treated again with low-dose aspirin (5) (6) (7) . Bleeding symptoms, aspirin side effects, and platelet counts in excess of 1,500 x 19/L were clear indications for cytoreductive treatment of ET ( Fig. 1 ). years. Twelve (17%) were <40 years, 26 (37%) were 40 to 60 years, and 28 (40%) were >60 years.
RESULTS
Platelet counts at presentation of 41 symptomatic ET patients with microcirculatory disturbances ranged from 400 to 1,400 with a mean of 750 x 109/L. Platelet count at time of bleeding symptoms in 5 ET patients at presentation and in 9 ET patients on aspirin during followup were in excess of 1,000 x 109/L in 12 cases (Figs. 1   and 3 ).
Risk factors for thrombosis ' '
Stepwise logistic regression analysis using the backwards elimination method, in which a number of risk factors were introduced simultaneously, revealed a previous microvascular or major thrombotic event as the only risk factor for recurrent thrombosis at presentation in ET. Neither stepwise logistic regression analysis nor testing single factors using a Chi-square test or Fisher's s exact test identified smoking, hypertension, hyperlipidemia, diabetes, alcohol, sex, or age as a significant risk factor for thrombosis in ET ( From 1974 to 1986, 20 symptomatic ET patients with microvascular circulation disturbances including active erythromelalgia (N = 18), a history of atypical and typical transient ischemic attacks (N = 6), or acute coronary syndrome (N = 3) were treated with one course of busulfan under weekly control of the platelet counts. Busulfan treatment was started at a dose of 4 or 6 mg/day at platelet counts > 1,000 x 109/L and was reduced to 2 mg/day as soon as the platelet count had dropped < 1,000
x 109/L. At a platelet count below 1,000 x 109/L, busulfan treatment was started at a dose of 4 mg/day for only a few weeks and reduced to 2 mg/day. Busulfan treatment was discontinued in all 20 ET patients at the time that the platelet counts were below the upper limit of normal 350 x 109/L (Figs. 4 and 5). At time of complete remission of ET, aspirin was discontinued until the patients became symptomatic. The mean platelet count before and after busulfan treatment was 1,009, (range 545-1,525) and 241 (range 159 to 315) x 109/L, respectively (Fig. 6 ). The total dose of one course of busulfan treatment ranged from 106 to 484 (mean 315) mg (Fig. 7) . The duration of the busulfan courses ranged from 44 to 218 (mean 116) days (Fig. 7 ). All 20 patients with ET in remission remained asymptomatic after discontinuation of busulfan and aspirin. None of the ET patients became symptomatic as long as ET was in maintained remission for 4 to 61 (mean 36) months. Eight patients became symptomatic and four patients remained asymptomatic at relapse of ET after a follow-up period of 19 to 61 and 31 to 46 months, respectively. Platelet counts at time of symptomatic relapse of ET in the eight patients were 410, 450, 490, 500, 515, 545, 548, and 635 x 109/L, and platelet counts at time of asymptomatic relapse of ET in the four patients were 577, 600, 648, and 725 x 109/L. Based on these observations, since 1986 we treated our ET patients with aspirin at time of presentation, follow-up, and at relapse as long as platelet counts were between 400 to 1,000 x 109/L up to 1250 x 109/L. Hydroxyurea became the drug of choice for clear indications to reduce the platelet count (17) (18) (19) . Bleeding symptoms, aspirin side effects, and platelet counts in excess of 1,000 to 1,250 x 109/L were clear indications for correction of platelet counts in ET with hydroxyurea (17) (18) (19) .
Conversion of essential thrombocythemia
In 10 of 68 (15%) ET patients a progression towards another myeloproliferative disorder was observed. Six patients developed polycythemia vera after a mean of 4.9 years, one progressed to a myelodysplastic syndrome af- FIG. 6. Platelet counts before and after busulfan treatment and at symptomatic relapse in patients with essential thrombocythemia. years after diagnosis of ET, respectively. Retrospectively, of the four patients who developed overt IMF, three had overt signs of hypercellular early stage IMF without or with reticulin, but no collagen fibrosis in the initial bone marrow biopsy. The fourth patient developed thrombocythemia during long-term follow-up of IMF as described in detail elsewhere (11) .
Survival analysis
During long-term follow-up (mean 6.2 years), 7 of 68 (10%) ET patients, 6 males and 1 female, ranging in age from 59 to 79 (mean 72) years died 6 ± 6 years after diagnosis due to pulmonary embolism, pneumonia, prostate cancer (3 cases), cardiac insufficiency after recurrent myocardial infarctions while on oral anticoagulant treatment in one patient (as described in detail elsewhere) (20) , hemorrhagic stroke during high-dose aspirin in one patient, and end-stage myelofibrosis with myeloid metaplasia followed by leukemic transformation in one patient who had overt early stage IMF in the initial bone marrow biopsy. In one patient the cause of death was unknown. The overall 5-and 10-year survival probability of all 68 ET patients was 93% and 84%, respectively ( Fig. 8 ). No thrombotic deaths were observed except in one ET patient with a history of recurrent aspirinsensitive microvascular thrombotic events who was treated for recurrent myocardial infarctions with oral anticoagulation but not with aspirin (20) . DISCUSSION By recognizing platelet-mediated and aspirin-responsive erythromelalgia as a specific early presenting symptom of ET (5, 6) and by prospective documentation of peripheral blood and bone marrow specimens, we were able to define the very early stages of the disease by a new set of diagnostic criteria of ET (7, 13, 14) . A sustained increase of the peripheral blood platelet count in excess of 400 x 109/L and an increase of clustered mature giant megakaryocytes with hyperploid nuclei in bone marrow specimens of biopsy material firmly establish the diagnosis of ET and differentiate ET from reactive thrombocytosis and from thrombocythemia as the presenting symptom of early stage idiopathic myelofibrosis or any other underlying cause of increased platelet counts (7, 9, 13, 14) .
Complete relief and elimination of microcirculatory disturbances, including erythromelalgia and transient cerebral and coronary ischemic manifestations, with aspirin, because of its irreversible inhibition of platelet cyclooxygenase activity, indicates that the microcirculatory events are provoked by intravascular activation and aggregation of platelets, which preferentially takes place at high shear rates in the endarterial circulation of the peripheral cerebral and coronary circulation (5) (6) (7) (8) (9) (10) (11) 16) . Maintained control of platelet function with low-dose aspirin appears to be effective and safe for many years with no progression of ET at a platelet count between 400 and 1,000 to 1,250 x 10~/L. Reduction of the plate-let count with busulfan to normal (<400 x 109/L) also eliminates the microcirculatory disturbances (7, 16, 18, 19) . Remission of ET after busulfan treatment with normal platelet counts for 1 to 9 years was associated with no recurrence of thrombotic events as long as the platelet counts remained normal (5, 7, 16) . Clear indications to reduce the platelet count, which became apparent during the study in a minority of the ET patients, were bleeding manifestations at platelet count in excess of 1,000 to 1,500 x 109/L and aspirin side effects (18, 19) . This nonleukemogenic or least toxic approach during the years since 1975 is the rationale behind the ultimate normal life expectancy and subsequent thrombosis-free survival in the recently reported update of 68 ET patients after a mean follow-up of 6.2 years (18) .
